SQZ BIOTECHNOLOGIES CO (SQZ) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:SQZ - US78472W1045 - Common Stock
SQZ Key Statistics, Chart & Performance
The current stock price of SQZ is 0.435 USD. In the past month the price decreased by -27.5%. In the past year, price decreased by -87.5%.
SQZ Latest News, Press Relases and Analysis
SQZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About SQZ
Company Profile
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Company Info
SQZ BIOTECHNOLOGIES CO
200 Arsenal Yards Blvd, Suite 210
Watertown MASSACHUSETTS 02472 US
CEO: Armon Sharei
Employees: 53
Phone: 16177588672.0
SQZ BIOTECHNOLOGIES CO / SQZ FAQ
Can you describe the business of SQZ BIOTECHNOLOGIES CO?
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
What is the current price of SQZ stock?
The current stock price of SQZ is 0.435 USD. The price increased by 61.11% in the last trading session.
Does SQZ stock pay dividends?
SQZ does not pay a dividend.
What is the ChartMill rating of SQZ BIOTECHNOLOGIES CO stock?
SQZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is SQZ stock listed?
SQZ stock is listed on the New York Stock Exchange exchange.
How is the valuation of SQZ BIOTECHNOLOGIES CO (SQZ) based on its PE ratio?
SQZ BIOTECHNOLOGIES CO (SQZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.45).
Is SQZ BIOTECHNOLOGIES CO (SQZ) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SQZ.
SQZ Technical Analysis
SQZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SQZ. SQZ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SQZ Financial Highlights
Over the last trailing twelve months SQZ reported a non-GAAP Earnings per Share(EPS) of -2.45. The EPS increased by 7.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SQZ Forecast & Estimates
6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 65.7% for SQZ